SCHEMBL6330964

SCHEMBL6330964

CCOc1ccc(S(=O)(=O)N(C)CC(C)O)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 1/20 0.52
ALDH1A1 P00352 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA7 P43166 1/20 0.49
CA9 Q16790 1/20 0.49
TDP1 Q9NUW8 2/20 0.47
CNR2 P34972 1/20 0.47
CCR5 P51681 1/20 0.44
LMNA P02545 1/20 0.44
POLB P06746 1/20 0.44
MMP3 P08254 3/20 0.44
KMT2A Q03164 2/20 0.44
MAPT P10636 2/20 0.43
MEN1 O00255 1/20 0.43
TP53 P04637 1/20 0.43
MMP1 P03956 1/20 0.42
MMP2 P08253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6323461 0.89 CA12 (0.51) ADAM17CA12CA1CA2CA7
SCHEMBL6324867 0.85 ADAM17 (0.70) ADAM17ALDH1A1SMN1; SMN2CA12CA1
SCHEMBL6325698 0.85 KEAP1 (0.51) ADAM17ALDH1A1MMP3MMP1MMP2
SCHEMBL6325897 0.83 MMP2 (0.60) ADAM17CA12CA1CA2CA7
SCHEMBL7414913 0.82 ADAM17 (0.77) ADAM17MMP1MMP2MMP7MMP9
SCHEMBL6324820 0.82 LMNA (0.62) ADAM17ALDH1A1SMN1; SMN2CCR5LMNA
SCHEMBL22104936 0.80 CA12 (0.56) ADAM17ALDH1A1SMN1; SMN2CA12CA1
SCHEMBL6321482 0.80 ESR1 (0.53) ADAM17CCR5LMNAMAPT
SCHEMBL22104632 0.78 CA12 (0.54) ALDH1A1SMN1; SMN2CA12CA1CA2
SCHEMBL6325888 0.78 KMT2A (0.51) ALDH1A1SMN1; SMN2CCR5LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors PHARMACIA CORPORATION 2005-01-20 US disclosed
US-6747027-B1 SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 PHARMACIA CORPORATION 2004-06-08 US disclosed
CN-1238688-A Thiol sulfonamide metalloprotease inhibitors MONSANTO CO (US) 1999-12-15 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors MMP12, MMP13, MMP3 ADAM17 27/4885ALDH1A1 986/4885SMN1; SMN2 2514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.